• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kymera Therapeutics Inc (NQ: KYMR )

    46.47 +0.30 (+0.65%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 432,609
    Open 47.10
    Bid (Size) 42.53 (1)
    Ask (Size) 46.41 (1)
    Prev. Close 46.17
    Today's Range 45.20 - 47.65
    52wk Range 9.600 - 53.27
    Shares Outstanding 55,307,775
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Latest Analyst Ratings For Kymera Therapeutics
    Via Benzinga
    Preview: Kymera Therapeutics's Earnings
    Via Benzinga

    Performance

    YTD
    +83.31%
    +83.31%
    1 Month
    +3.27%
    +3.27%
    3 Month
    +10.54%
    +10.54%
    6 Month
    +24.25%
    +24.25%
    1 Year
    +284.69%
    +284.69%

    More News

    Read More
    Insights Ahead: Kymera Therapeutics's Quarterly Earnings
    Via Benzinga
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Via Benzinga
    The Analyst Landscape: 7 Takes On Kymera Therapeutics
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
    Via Benzinga
    Unveiling 6 Analyst Insights On Kymera Therapeutics
    Via Benzinga
    Why Kymera Therapeutics Stock Is Soaring Today
    Via The Motley Fool
    Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
    Via Benzinga
    Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
    Via Benzinga
    This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    Via FinancialNewsMedia
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    From FN Media Group LLC
    Via GlobeNewswire
    Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Therapeutics to Participate in Upcoming June Investor Conferences
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
    From Kymera Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.